

# Pericarditis - Pipeline Insight, 2021

<https://marketpublishers.com/r/P01038BD3E91EN.html>

Date: February 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: P01038BD3E91EN

## Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Pericarditis - Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Pericarditis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

## Geography Covered

Global coverage

## Pericarditis Understanding

### Pericarditis: Overview

Pericarditis is characterized by swelling and irritation in the pericardial sac, and often a pericardial effusion. The condition causes sharp chest pain when the irritated pericardium layer rub against each other. It can be grouped into different categories which include acute pericarditis, recurrent pericarditis, incessant, and chronic constrictive pericarditis. Pericarditis occurs in people of all ages, although viral pericarditis is more common in adults than in children. In contrast, purulent pericarditis is common in children. Although, pericarditis is usually mild and does not require treatment however, more severe cases may include medications such as colchicine, pain relievers, corticosteroids and surgeries in very rare cases.

"Pericarditis - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive

insights of present scenario and growth prospects across the indication. A detailed picture of the Pericarditis pipeline landscape is provided which includes the disease overview and Pericarditis treatment guidelines. The assessment part of the report embraces, in depth Pericarditis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pericarditis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Pericarditis R&D. The therapies under development are focused on novel approaches to treat/improve Pericarditis.

### Pericarditis Emerging Drugs Chapters

This segment of the Pericarditis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

### Pericarditis Emerging Drugs

#### Rilonacept: Kiniska Pharmaceuticals

Rilonacept is a recombinant fusion protein. It is currently being developed for the treatment of pericarditis. The drug molecule is in pre-registration phase and has been designated with orphan drug status for pericarditis disease. It interrupts the IL-1 beta signaling by binding itself with IL-1 beta and further prevents its binding with IL-1 cell surface receptors.

#### RPH-104: R Internat-Pharm ional, LLC

RPH-104 is an anti-inflammatory drug molecule currently in Phase II/III of the clinical trials for the treatment of pericarditis. The drug molecule works on Interleukin-1 beta inhibitor mechanism.

Further product details are provided in the report.....

### Pericarditis: Therapeutic Assessment

This segment of the report provides insights about the different Pericarditis drugs segregated based on following parameters that define the scope of the report, such as:

### Major Players in Pericarditis

There are approx. 3+ key companies which are developing the therapies for Pericarditis. The companies which have their Pericarditis drug candidates in the most advanced stage, i.e. phase pre-registration include, Kiniska Pharmaceuticals.

### Phases

DelveInsight's report covers around 3+ products under different phases of clinical development like

- Late stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

### Route of Administration

Pericarditis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Oral

- Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

## **Product Type**

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pericarditis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pericarditis therapeutic drugs key players involved in developing key drugs.

## **Pipeline Development Activities**

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pericarditis drugs.

Pericarditis Report Insights

Pericarditis Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Pericarditis Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## **Key Questions**

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Pericarditis drugs?

How many Pericarditis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pericarditis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pericarditis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Pericarditis and their status?

What are the key designations that have been granted to the emerging drugs?

### **Key Players**

Kiniska Pharmaceuticals

R-Pharm International, LLC

### **Key Products**

Rilonacept

RPH-104

## Contents

Introduction

Executive Summary

Pericarditis: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Pericarditis – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Pericarditis companies' collaborations, Licensing, Acquisition -Deal Value Trends

Pericarditis Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Pre-registration)

Comparative Analysis

Rilonacept: Kiniska Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Late Stage Products (Phase II/III)

Comparative Analysis

RPH-104: R-Pharm International, LLC

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis  
Pericarditis Key Companies  
Pericarditis Key Products  
Pericarditis- Unmet Needs  
Pericarditis- Market Drivers and Barriers  
Pericarditis- Future Perspectives and Conclusion  
Pericarditis Analyst Views  
Pericarditis Key Companies  
Appendix



## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Pericarditis

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for Pericarditis
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: Pericarditis - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/P01038BD3E91EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P01038BD3E91EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970